Abstract | BACKGROUND: PATIENTS AND METHODS: Sixty patients with FL received ASCT in our institution (18 first-line with total body irradiation and cyclophosphamide, 34 second-line with BEAM and 8 ≥ third-line with BEAM). In the case of long-term remission (>6 years; N = 17), peripheral blood was tested for minimal residual disease by t(14;18)- and IGH-PCR. RESULTS: Ten-year overall survival, progression-free survival and freedom from progression (FFP) after first-line ASCT were 79%, 57% and 64% after second-line ASCT 41%, 35% and 42%, respectively. Prognostic factors for FFP were treatment line and FLIPI ( Follicular Lymphoma International Prognostic Index). Ten-year FFP for second-line ASCT and low-risk FLIPI was 57%, intermediate risk 37% and high risk 33%. No relapses occurred after 6 years following ASCT. Sixteen patients developed sustained long-term clinical and molecular remissions of up to 17.5 years. CONCLUSION: Sustained long-term clinical and molecular remissions can be achieved following ASCT, including HDT with BEAM in second line.
|
Authors | B Metzner, C Pott, T H Müller, W Gebauer, J Casper, D Kraemer, B Rosien, S Schumann-Binarsch, R Thole, C H Köhne |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 24
Issue 6
Pg. 1609-15
(Jun 2013)
ISSN: 1569-8041 [Electronic] England |
PMID | 23393125
(Publication Type: Journal Article)
|
Chemical References |
- Cytarabine
- Podophyllotoxin
- Melphalan
- Carmustine
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Carmustine
(administration & dosage)
- Cohort Studies
- Combined Modality Therapy
(methods, mortality)
- Cytarabine
(administration & dosage)
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Lymphoma, Follicular
(drug therapy, mortality, surgery)
- Male
- Melphalan
(administration & dosage)
- Middle Aged
- Podophyllotoxin
(administration & dosage)
- Remission Induction
(methods)
- Stem Cell Transplantation
(methods, mortality)
- Time Factors
- Transplantation, Autologous
- Treatment Outcome
|